Home › Companies › Palisade Bio, Inc. › 2025-2026
At Palisade Bio, Inc.'s 3 shareholder meetings in the 2025-2026 proxy season (held October 17, 2025, December 3, 2025 and June 10, 2026), 57 asset managers reported how they voted on 18 ballot items in their SEC Form N-PX filings, covering 285 separate fund positions. On the most widely held item of the season, voted at the meeting held June 10, 2026 — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS… — Palisade Bio, Inc.'s filing reports the proposal as approved, with 70% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Palisade Bio, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Palisade Bio, Inc.’s Form 8-K, filed June 11, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 10, 2026: 10 items on Palisade Bio, Inc.’s Form 8-K, filed June 11, 2026: 6 approved · 4 without a stated outcome.
Meeting of December 3, 2025: 3 items on Palisade Bio, Inc.’s Form 8-K, filed December 4, 2025: 3 approved.
Meeting of October 17, 2025: 5 items on Palisade Bio, Inc.’s Form 8-K, filed October 20, 2025: 2 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Palisade Bio, Inc. in the interactive database Compare manager voting policies
These tallies are Palisade Bio, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. Palisade Bio, Inc. reported 3 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: J.D. Finley | 106,600,509 | -- | -- | 2,266,840 | 21,036,704 | 98% | Not verified | — |
| Elect Director: Donald Williams | 78,962,735 | -- | -- | 29,904,615 | 21,036,704 | 73% | Not verified | — |
| Elect Director: Emil Chuang | 99,500,152 | -- | -- | 9,367,198 | 21,036,704 | 91% | Not verified | — |
| Elect Director: Robert F. Baltera, Jr. | 108,502,141 | -- | -- | 365,209 | 21,036,704 | 99.6% | Not verified | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 129,320,182 | 34,669 | 549,203 | -- | -- | 99.9% | Approved | — |
| 3. Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock | 128,093,623 | 871,548 | 938,883 | -- | -- | 99.3% | Approved | — |
| 4. Approval of the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan | 92,245,546 | 14,658,772 | 1,963,032 | -- | 21,036,704 | 86% | Approved | — |
| 5. Approval of the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan | 108,167,158 | 162,907 | 537,285 | -- | 21,036,704 | 99.8% | Approved | — |
| 6. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement | 75,273,044 | 31,773,692 | 1,820,614 | -- | 21,036,704 | 70% | Approved | — |
| 7. Approval of equity award grants to our non-employee directors | 82,713,960 | 24,332,309 | 1,821,081 | -- | 21,036,704 | 77% | Approved | — |
Source: Palisade Bio, Inc., Form 8-K, filed with the SEC on June 11, 2026 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. Warrant Exercise Proposal | 104,727,000 | 247,103 | 10,386 | -- | 22,419,519 | 99.7% | Approved | — |
| 2. Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock | 126,272,110 | 1,095,166 | 36,732 | -- | -- | 99.1% | Approved | — |
| 3. Adjournment Proposal | 126,487,729 | 867,738 | 48,541 | -- | -- | 99.3% | Approved | — |
Source: Palisade Bio, Inc., Form 8-K, filed with the SEC on December 4, 2025 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: J.D. Finley | 647,086 | -- | -- | 89,445 | 2,849,169 | 88% | Not verified | — |
| Elect Director: Donald Williams | 641,789 | -- | -- | 94,742 | 2,849,169 | 87% | Not verified | — |
| Elect Director: Emil Chuang | 659,895 | -- | -- | 76,636 | 2,849,169 | 90% | Not verified | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 3,348,348 | 108,424 | 128,928 | -- | -- | 97% | Approved | — |
| 3. Approval of an Amendment to the Amended and Restated Certificate of Incorporation to effect, at the Discretion of the Board of Directors, a Reverse Stock Split | 2,353,265 | 1,122,616 | 109,819 | -- | -- | 68% | Approved | — |
Source: Palisade Bio, Inc., Form 8-K, filed with the SEC on October 20, 2025 — read the filing on EDGAR.
Each item below shows how the 57 asset managers that disclosed a Palisade Bio, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held June 10, 2026.
Combines 2 wordings of this item as funds reported it.
73% Majority: yes · of votes cast
Description as filed by funds: To elect four directors to hold office until the 2027 Annual Meeting of Stockholders or until a successor is duly elected and qualified or until the director's earlier death, resignation or removal: Donald Williams
Palisade Bio, Inc.’s own tally for this item (“Elect Director: Donald Williams”): 78,962,735 for, 29,904,615 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 3,884,512 for, 4,537,375 withheld, 55 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 0 | 0 | 0 | 3,136,607 | Withhold |
| FRANKLIN STRATEGIC SERIES | 2,119,910 | 0 | 0 | 0 | For |
| Vanguard | 1,414,602 | 0 | 55 | 9,663 | For |
| Fidelity | 0 | 0 | 0 | 1,261,302 | Withhold |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 76,000 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 32,796 | Withhold |
| Victory Capital | 0 | 0 | 0 | 16,454 | Withhold |
| American Century | 0 | 0 | 0 | 4,553 | Withhold |
Meeting held June 10, 2026.
Combines 2 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Description as filed by funds: To elect four directors to hold office until the 2027 Annual Meeting of Stockholders or until a successor is duly elected and qualified or until the director's earlier death, resignation or removal: Emil Chuang
Palisade Bio, Inc.’s own tally for this item (“Elect Director: Emil Chuang”): 99,500,152 for, 9,367,198 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 5,171,782 for, 3,250,148 withheld, 13 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 0 | 0 | 0 | 3,136,607 | Withhold |
| FRANKLIN STRATEGIC SERIES | 2,119,910 | 0 | 0 | 0 | For |
| Vanguard | 1,419,563 | 0 | 13 | 4,745 | For |
| Fidelity | 1,261,302 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 76,000 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 32,796 | Withhold |
| Victory Capital | 16,454 | 0 | 0 | 0 | For |
| American Century | 4,553 | 0 | 0 | 0 | For |
Meeting held June 10, 2026.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect four directors to hold office until the 2027 Annual Meeting of Stockholders or until a successor is duly elected and qualified or until the director's earlier death, resignation or removal: J.D. Finley
Palisade Bio, Inc.’s own tally for this item (“Elect Director: J.D. Finley”): 106,600,509 for, 2,266,840 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 8,417,193 for, 4,745 withheld, 5 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 3,136,607 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,119,910 | 0 | 0 | 0 | For |
| Vanguard | 1,419,571 | 0 | 5 | 4,745 | For |
| Fidelity | 1,261,302 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 76,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 32,796 | 0 | 0 | 0 | For |
| Victory Capital | 16,454 | 0 | 0 | 0 | For |
| American Century | 4,553 | 0 | 0 | 0 | For |
Meeting held June 10, 2026.
Combines 2 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: To elect four directors to hold office until the 2027 Annual Meeting of Stockholders or until a successor is duly elected and qualified or until the director's earlier death, resignation or removal: Robert F. Baltera, Jr.
Palisade Bio, Inc.’s own tally for this item (“Elect Director: Robert F. Baltera, Jr.”): 108,502,141 for, 365,209 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 8,421,942 for, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 3,136,607 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,119,910 | 0 | 0 | 0 | For |
| Vanguard | 1,424,320 | 0 | 1 | 0 | For |
| Fidelity | 1,261,302 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 76,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 32,796 | 0 | 0 | 0 | For |
| Victory Capital | 16,454 | 0 | 0 | 0 | For |
| American Century | 4,553 | 0 | 0 | 0 | For |
Meeting held October 17, 2025.
87% Majority: yes · of votes cast
Description as filed by funds: To elect three directors to hold office until the 2026 Annual Meeting of Stockholders or until a successor is duly elected and qualified or until the director's earlier death, resignation or removal: Donald Williams
Palisade Bio, Inc.’s own tally for this item (“Elect Director: Donald Williams”): 641,789 for, 94,742 withheld, per its Form 8-K filed October 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 3,117 for, 302 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,117 | 0 | 0 | 0 | For |
| Fidelity | 0 | 0 | 0 | 302 | Withhold |
Meeting held October 17, 2025.
90% Majority: yes · of votes cast
Description as filed by funds: To elect three directors to hold office until the 2026 Annual Meeting of Stockholders or until a successor is duly elected and qualified or until the director's earlier death, resignation or removal: Emil Chuang
Palisade Bio, Inc.’s own tally for this item (“Elect Director: Emil Chuang”): 659,895 for, 76,636 withheld, per its Form 8-K filed October 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 3,419 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,117 | 0 | 0 | 0 | For |
| Fidelity | 302 | 0 | 0 | 0 | For |
Meeting held October 17, 2025.
88% Majority: yes · of votes cast
Description as filed by funds: To elect three directors to hold office until the 2026 Annual Meeting of Stockholders or until a successor is duly elected and qualified or until the director's earlier death, resignation or removal: J.D. Finley
Palisade Bio, Inc.’s own tally for this item (“Elect Director: J.D. Finley”): 647,086 for, 89,445 withheld, per its Form 8-K filed October 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 3,419 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,117 | 0 | 0 | 0 | For |
| Fidelity | 302 | 0 | 0 | 0 | For |
Meeting held June 10, 2026.
Combines 2 wordings of this item as funds reported it.
99.3% Approved · of votes cast
Description as filed by funds: To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 (which will result in an increase in the total number of authorized shares of capital stock of the Company from 307,000,000 to 457,000,000.
Palisade Bio, Inc.’s own tally for this item (“3. Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock”): 128,093,623 for, 871,548 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 (which will result in an increase in the total number of authorized shares of capital stock…”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 8,421,941 for, 1 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 3,136,607 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,119,910 | 0 | 0 | 0 | For |
| Vanguard | 1,424,319 | 1 | 1 | 0 | For |
| Fidelity | 1,261,302 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 76,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 32,796 | 0 | 0 | 0 | For |
| Victory Capital | 16,454 | 0 | 0 | 0 | For |
| American Century | 4,553 | 0 | 0 | 0 | For |
Meeting held December 3, 2025.
99.1% Approved · of votes cast
Description as filed by funds: To approve an amendment to our Amended and Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation") to increase the number of authorized shares of common stock from 280,000,000 to 300,000,000 (which will result in an increase in the total number of authorized shares of capital stock of the Company from 287,000,000 to 307,000,000). We refer to this proposal as the "Increased Authorized Shares Proposal" or "Proposal 2."
Palisade Bio, Inc.’s own tally for this item (“2. Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock”): 126,272,110 for, 1,095,166 against — passed, per its Form 8-K filed December 4, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 280,000,000 to 300,000,000 (which will result in an increase in the total number of authorized shares of capital stock…”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 1,603,442 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FRANKLIN STRATEGIC SERIES | 1,599,923 | 0 | 0 | 0 | For |
| Vanguard | 3,117 | 0 | 0 | 0 | For |
| Fidelity | 402 | 0 | 0 | 0 | For |
Meeting held December 3, 2025.
99.7% Approved · of votes cast
Description as filed by funds: To approve, pursuant to Nasdaq Listing Rule 5635(d), the issuance of up to 8,637,810 shares of our common stock underlying certain warrants issued by us pursuant to the terms of that certain warrant inducement agreement dated as of July 23, 2025, which is equal to or in excess of 20% of our common stock outstanding prior to the issuance of such warrants. We refer to this proposal as the "Warrant Exercise Proposal" or "Proposal 1."
Palisade Bio, Inc.’s own tally for this item (“1. Warrant Exercise Proposal”): 104,727,000 for, 247,103 against — passed, per its Form 8-K filed December 4, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1: Warrant Exercise Proposal”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 1,603,442 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FRANKLIN STRATEGIC SERIES | 1,599,923 | 0 | 0 | 0 | For |
| Vanguard | 3,117 | 0 | 0 | 0 | For |
| Fidelity | 402 | 0 | 0 | 0 | For |
Meeting held October 17, 2025.
68% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect, at the discretion of the Company's Board of Directors: a reverse split of the Company's common stock, at a ratio of not less than 1-for-5 and not greater than 1-for-50, with the exact ratio to be set within that range at the discretion of the Board of Directors, without further approval or authorization of our stockholders, and to be effected on or before December 31, 2025.
Palisade Bio, Inc.’s own tally for this item (“3. Approval of an Amendment to the Amended and Restated Certificate of Incorporation to effect, at the Discretion of the Board of Directors, a Reverse Stock Split”): 2,353,265 for, 1,122,616 against — passed, per its Form 8-K filed October 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation to effect, at the discretion of the board of directors, a reverse split of the Company's common stock at a ratio of not less than 1-for-5 and not greater than 1-for-50, with the exact…”
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 3,419 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,117 | 0 | 0 | 0 | For |
| Fidelity | 302 | 0 | 0 | 0 | For |
Meeting held December 3, 2025.
99.3% Approved · of votes cast
Description as filed by funds: To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the foregoing proposals. We refer to this as the "Adjournment Proposal" or "Proposal 3."
Palisade Bio, Inc.’s own tally for this item (“3. Adjournment Proposal”): 126,487,729 for, 867,738 against — passed, per its Form 8-K filed December 4, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved a proposal to adjourn the Special Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of any of the foregoing proposals.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 1,603,442 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| FRANKLIN STRATEGIC SERIES | 1,599,923 | 0 | 0 | 0 | For |
| Vanguard | 3,117 | 0 | 0 | 0 | For |
| Fidelity | 402 | 0 | 0 | 0 | For |
Meeting held June 10, 2026.
Combines 3 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To approve the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan.
Palisade Bio, Inc.’s own tally for this item (“5. Approval of the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan”): 108,167,158 for, 162,907 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 3,136,607 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,119,910 | 0 | 0 | 0 | For |
| Vanguard | 1,424,320 | 0 | 1 | 0 | For |
| Fidelity | 1,261,302 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 76,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 32,796 | 0 | 0 | 0 | For |
| Victory Capital | 16,454 | 0 | 0 | 0 | For |
| American Century | 4,553 | 0 | 0 | 0 | For |
Fund voting reports, all 9 managers: 8,421,942 for, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| B Group, Inc. | 10,367,427 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 1,399,065 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 11,766,492 for.
Meeting held June 10, 2026.
Combines 2 wordings of this item as funds reported it.
77% Approved · of votes cast
Description as filed by funds: To approve equity award grants to our non-employee directors.
Palisade Bio, Inc.’s own tally for this item (“7. Approval of equity award grants to our non-employee directors”): 82,713,960 for, 24,332,309 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved equity grants to the Company's non-employee directors.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 0 | 3,136,607 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 2,119,910 | 0 | 0 | 0 | For |
| Vanguard | 12,290 | 1,412,028 | 3 | 0 | Against |
| Fidelity | 0 | 1,261,302 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 76,000 | 0 | 0 | Against |
| Goldman Sachs | 0 | 32,796 | 0 | 0 | Against |
| Victory Capital | 0 | 16,454 | 0 | 0 | Against |
| American Century | 0 | 4,553 | 0 | 0 | Against |
Fund voting reports, all 9 managers: 2,482,200 for, 5,939,740 against, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| B Group, Inc. | 10,367,427 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 8,802,279 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 19,169,706 for.
Meeting held June 10, 2026.
Combines 2 wordings of this item as funds reported it.
86% Approved · of votes cast
Description as filed by funds: To approve the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan.
Palisade Bio, Inc.’s own tally for this item (“4. Approval of the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan”): 92,245,546 for, 14,658,772 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan.”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 3,136,607 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,119,910 | 0 | 0 | 0 | For |
| Vanguard | 1,419,371 | 4,947 | 4 | 0 | For |
| Fidelity | 0 | 1,261,302 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 76,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 32,796 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 16,454 | 0 | 0 | Against |
| American Century | 0 | 4,553 | 0 | 0 | Against |
Fund voting reports, all 9 managers: 7,134,684 for, 1,287,256 against, 4 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| B Group, Inc. | 10,367,427 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 10,367,427 for.
Meeting held June 10, 2026.
Combines 4 wordings of this item as funds reported it.
70% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.
Palisade Bio, Inc.’s own tally for this item (“6. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement”): 75,273,044 for, 31,773,692 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 0 | 3,136,607 | 0 | 0 | Against |
| FRANKLIN STRATEGIC SERIES | 0 | 2,119,910 | 0 | 0 | Against |
| Vanguard | 12,273 | 1,412,044 | 3 | 0 | Against |
| Fidelity | 0 | 1,261,302 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 76,000 | 0 | 0 | Against |
| Goldman Sachs | 0 | 32,796 | 0 | 0 | Against |
| Victory Capital | 0 | 16,454 | 0 | 0 | Against |
| American Century | 0 | 4,553 | 0 | 0 | Against |
Fund voting reports, all 9 managers: 362,273 for, 8,059,666 against, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 16,565,784 | 0 | 0 | 0 | For |
| B Group, Inc. | 10,367,427 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 9,505,065 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 9,490,541 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 8,802,279 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 7,124,116 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 6,811,514 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 0 | 5,785,189 | 0 | 0 | Against |
| Commodore Capital LP | 5,085,612 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 4,500,000 | 0 | 0 | Against |
| Federated Hermes | 0 | 3,136,607 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 0 | 2,333,000 | 0 | 0 | Against |
| Wellington | 0 | 2,131,328 | 0 | 0 | Against |
| HighVista Strategies LLC | 2,019,326 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 2,000,000 | 0 | 0 | 0 | For |
| Artia Global Partners LP | 1,992,367 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 0 | 1,933,037 | 0 | 0 | Against |
| MARSHALL WACE, LLP | 0 | 1,852,251 | 0 | 0 | Against |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 1,794,594 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 1,556,009 | 0 | 0 | Against |
| Vestal Point Capital, LP | 0 | 1,455,519 | 0 | 0 | Against |
| Eversept Partners, LP | 1,399,065 | 0 | 0 | 0 | For |
| PLATINUM INVESTMENT MANAGEMENT LTD | 0 | 0 | 1,231,414 | 0 | Abstain |
| Aberdeen | 0 | 1,106,400 | 0 | 0 | Against |
| BlackRock | 0 | 913,640 | 0 | 0 | Against |
No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held June 10, 2026.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Baker Tilly US, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
Palisade Bio, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 129,320,182 for, 34,669 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 9 asset managers below reported 8,421,942 for, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Federated Hermes | 3,136,607 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 2,119,910 | 0 | 0 | 0 | For |
| Vanguard | 1,424,320 | 0 | 1 | 0 | For |
| Fidelity | 1,261,302 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 350,000 | 0 | 0 | 0 | For |
| Charles Schwab | 76,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 32,796 | 0 | 0 | 0 | For |
| Victory Capital | 16,454 | 0 | 0 | 0 | For |
| American Century | 4,553 | 0 | 0 | 0 | For |
Meeting held October 17, 2025.
97% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Baker Tilly US, LLP, as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
Palisade Bio, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 3,348,348 for, 108,424 against — passed, per its Form 8-K filed October 20, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 2 asset managers below reported 3,419 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,117 | 0 | 0 | 0 | For |
| Fidelity | 302 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 173,579,670 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Federated Hermes | 1.81% |
| 2 | FRANKLIN STRATEGIC SERIES | 1.22% |
| 3 | Vanguard | 0.82% |
| 4 | Fidelity | 0.73% |
| 5 | Simplify Exchange Traded Funds | 0.20% |
| 6 | Charles Schwab | 0.04% |
| 7 | Goldman Sachs | 0.02% |
| 8 | Victory Capital | <0.01% |
| 9 | American Century | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 9.54% |
| 2 | B Group, Inc. | 5.97% |
| 3 | PERCEPTIVE ADVISORS LLC | 5.48% |
| 4 | AMERIPRISE FINANCIAL INC | 5.47% |
| 5 | Octagon Capital Advisors LP | 5.07% |
| 6 | RA CAPITAL MANAGEMENT, L.P. | 4.10% |
| 7 | GREAT POINT PARTNERS LLC | 3.92% |
| 8 | FRANKLIN ADVISERS INC | 3.33% |
| 9 | Commodore Capital LP | 2.93% |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.59% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 10.15% | 13G |
| Janus Henderson Investors US LLC | 9.96% | DEF14A |
| Commodore Capital LP | 8.36% | DEF14A |
| Perceptive Advisors LLC | 8.13% | 13G |
| Soleus Capital Master Fund, L.P. | 7.53% | 13G |
| Point72 Capital Advisors, Inc. | 6.05% | DEF14A |
| Octagon Capital Advisors LP | 5.51% | 13G |
| Franklin Resources, Inc. | 5.28% | 13G |
| Vanguard Capital Management | 5.18% | 13G |
| Ameriprise Financial, Inc. | 5.02% | 13G |
Percentages above are of 173,579,670 shares outstanding, as reported by Palisade Bio, Inc. on its Form 10-Q dated May 7, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Palisade Bio, Inc.’s 10-Q dated May 7, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Palisade Bio, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Palisade Bio (PALI) 2025-2026 Annual & Special Meetings: Vote Results”, https://proxyvotesnow.com/company/palisade-bio-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.